Melbourne-headquartered Cancer Therapeutics CRC (CTx) today announced a two-year research collaboration and a license agreement with Pfizer Inc. (NYSE: PFE). Under the terms of the agreement, Pfizer w...
In a world first, Melbourne scientists have discovered a new type of anti-cancer drug that can put cancer cells into a permanent sleep, without the harmful side-effects caused by conventional cancer t...
Cancer Therapeutics CRC (CTx), a small molecule oncology drug discovery and development group partnered with some of Australia’s pre-eminent medical research institutions, is pleased to announce two...
Cancer Therapeutics CRC (CTx) is proud to announce that it received the Australian CRC Association’s (CRCA) Award for Excellence in Innovation at the annual awards dinner in Canberra on 24 May. The...
CTx Chief Executive, Dr. Warwick Tong, today announced that a majority of its current partners have chosen to reinvest their share of the recent cash distribution from CTx back into the organisation....
CTx and its commercialisation partner Cancer Research Technology (CRT) are pleased to announce a multimillion dollar licensing deal with MSD, known as Merck in the US and Canada, to develop inhibit...
The Cancer Therapeutics CRC (CTx) is proud to announce our support for the ‘Zero Childhood Cancer’ program launched by the Children’s Cancer Institute (CCI) and The Sydney Children’s Hospitals...
Cancer Therapeutics CRC (CTx) receives AU$5.4 million Wellcome Trust Seeding Drug Discovery Award for novel approach to treating major blood disorders. CTx, headquartered in Melbourne and funded throu...
On 15 September 2014, CTx hosted a Launch event at the Royal Melbourne Hospital to acknowledge and celebrate the six years of Government, Industry and Research funding to drive the next phase of our w...